Zevra Therapeutics (ZVRA) drew fresh attention after reporting first quarter 2026 earnings, with sales of US$36.22 million and net income of US$37.89 million, compared with a net loss a year earlier.

The latest earnings headline has been met with strong buying interest, with the stock’s 1 day share price return of 6.03% helping extend a 34.89% year to date share price gain and a 1 year total shareholder return of 49.80%, which follows very large total shareholder returns over three years.

If Zevra’s move has you watching this part of the market more closely, it can be useful to see what else is gaining attention across rare disease drug developers and adjacent plays through our 32 healthcare AI stocks

With earnings now in the black and the stock already up strongly over one and three years, the key question is whether Zevra is still trading at a discount or if the market is already pricing in future growth.

Most Popular Narrative: 58.2% Undervalued

At a last close of $11.25 against a narrative fair value of $26.89, Zevra is being framed as a rare disease commercialisation story still priced like a pre-revenue biotech, according to Talos.

Zevra Therapeutics is at the most profitable inflection point in biotechnology: the transition from cash-burning R&D to cash-generating commercial sales. With the recent FDA approval of Miplyffa (for Niemann-Pick disease type C), Zevra has secured the first and only approved treatment for this ultra-rare condition. Combined with the sale of its Priority Review Voucher (PRV) for ~$100M non-dilutive cash, the balance sheet is fortified. The market is currently pricing ZVRA as a speculative biotech, failing to account for the high-margin, recurring revenue of a rare disease monopoly.

Want to see what sits behind that valuation jump, from cash-burning to cash-generating and a rare disease monopoly, plus a profit multiple usually reserved for larger pharma groups? The narrative leans heavily on rapid revenue expansion, rising margins and a future earnings profile that has to work hard to justify a fair value more than double the current price.

Result: Fair Value of $26.89 (UNDERVALUED)

However, this hinges on sustained demand for ultra rare disease drugs and smooth commercial execution, with any pricing, reimbursement or trial setbacks potentially challenging the upbeat story.

Next Steps

Feeling torn between the upbeat earnings story and the potential stumbling blocks? Take a closer look at the full set of trade offs through our 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Zevra has sharpened your interest in healthcare and growth stories, do not stop here, broaden your watchlist with ideas filtered for quality and resilience.

• Target potential mispricings by scanning companies screened as 45 high quality undervalued stocks so you can spot opportunities others might overlook.
• Prioritise financial strength by reviewing stocks highlighted in the solid balance sheet and fundamentals stocks screener (45 results) and focus on businesses with robust foundations.
• Get ahead of the crowd by tracking the screener containing 23 high quality undiscovered gems and see which underfollowed stocks meet strict fundamental checks before they gain wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.